Bard C R Inc /nj/ (BCR): Christopher S Holland , Senior Vice President and CFO of Bard C R Inc /nj/ sold 3,970 shares on May 27, 2016. The Insider selling transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were sold at $219.88 per share for a total value of $872,945.44 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 1, 2016, Christopher S Holland (Senior Vice President and CFO) sold 3,970 shares at $219.88 per share price.On May 18, 2016, John P Groetelaars (Group President) sold 1,162 shares at $219.88 per share price.Also, On May 16, 2016, Tommy G Thompson (director) sold 500 shares at $219.52 per share price.On May 9, 2016, Tony L White (director) sold 1,200 shares at $216.19 per share price.
Shares of C R Bard Inc (BCR) ended Friday, May 27, 2016 session in red amid volatile trading. The shares closed down -0.58 points or -0.26% at $219 with 4,54,880 shares getting traded. Post opening the session at $220, the shares hit an intraday low of $218.75 and an intraday high of $220.1499 and the price vacillated in this range throughout the day. The company has a market cap of $16,057 M and the number of outstanding shares has been calculated to be 7,33,18,689 shares. The 52-week high of C R Bard Inc is $223.02 and the 52-week low is $167.36.
Company has been under the radar of several Street Analysts.C R Bard Inc is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 224 from a previous price target of $212 .The Rating was issued on May 24, 2016.C R Bard Inc is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 212 from a previous price target of $195 .The Rating was issued on Apr 28, 2016.C R Bard Inc is Initiated by Nomura to Neutral. The Rating was issued on Mar 17, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.